Whole‐exome Sequencing Revealed Mutational Profiles of Giant Cell Glioblastomas

Zhi-feng Shi,Kay Ka-Wai Li,Johnny Sheung Him Kwan,Rui Ryan Yang,Abudumijiti Aibaidula,Qisheng Tang,Yifeng Bao,Ying Mao,Hong Chen,Ho-Keung Ng

DOI: https://doi.org/10.1111/bpa.12720

IF: 7.611

2019-01-01

Brain Pathology

Abstract:Giant cell glioblastoma (gcGBM) is a rare histological variant of GBM, accounting for about 1% of all GBM. The prognosis is poor generally though gcGBM does slightly better than the other IDH‐wild‐type GBM. Because of the rarity of the cases, there has been no comprehensive molecular analysis of gcGBM. Previously, single‐gene study identified genetic changes in TP53, PTEN and TERT promoter mutation in gcGBM. In this report, we performed whole‐exome sequencing (WES) to identify somatically acquired mutations and copy number variations (CNVs) in 10 gcGBM genomes. We also examined TERT promoter mutation and MGMT methylation in our cohort. On top of the reported mutations, WES revealed ATRX, PIK3R1, RB1 and SETD2 as the recurrent mutations in gcGBM. Notably, one tumor harbored a mutation in MutS homolog 6 (MSH6) that is a key mismatch repair (MMR) gene. This tumor demonstrated hypermutation phenotype and showed an increased number of somatic mutations. TERT promoter mutation and MGMT methylation were observed in 20% and 40% of our samples, respectively. In conclusion, we described relevant mutation profiling for developing future targeted therapies in gcGBM.